Spyre Therapeutics raises $463.5M in public offering to fund Phase 3 readiness
Filed April 16, 2026 · Period ending April 14, 2026 · ~1 min read
4 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade SYRE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 3, 2026 2:47 AM